Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ethyl

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Study title: A trial of Methyl Polysiloxane in the treatment of abdominal distension - Marks IN - 1965 (S.A. Med. J. 1965; 476-478) - Publication in Part IC3 of the FLATUNYL french dossier 1999 (MAALOX plus) - Bergmann JF - 06/01/1999 -A trial of Methyl Polysiloxane in the treatment of abdominal distension - Marks IN - 1965 (S.A. Med. J. 1965; 476-478) - Publication in Part IC3 of the FLATUNYL french dossier 1999 (MAALOX plus) - Bergmann JF - 06/01/1999 -
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46404
    Study title: Studie mit Hydro-, Lipo- und Sebonorm Cordes
    Active substance: Allantoin/ Dexpanthenol/Ethyl[(Z/Z)-octadeca-9,12-dienoat]
    Study summary document link (including results):
    View full study record
    Document reference: 39778
    Study title: Therapieerfahrungen mit Arnika und Hydroxyethylsalicylat in einem Akut-Spray
    Active substance: ARNICA AND SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 21831
    Study title: A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented with Either Extended-Release Methylphenidadte Hydrochloride (Concentra) or Plcebo in Children with Attention-Deficit/Hypractivity Disorder (ADHD) Who Have Not Reponded to Stimula
    Active substance: ATOMOXETINE
    Study summary document link (including results): atomoxetine B4Z-MC-LYBU Clinical study Summary.pdf
    View full study record
    Document reference: 21990
    Study title: A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride, Extended-Release Methylphenidate Hydrochloride (Concentra), and Placebo in Pediatric Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder
    Active substance: ATOMOXETINE
    Study summary document link (including results): atomoxetine B4Z-MC-LYBI - clinical study summary.pdf
    View full study record
    Document reference: 21971
    Study title: A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate Hydrochloride in Pediatric Outpaitents with DSM-IV Attention-Deficit/Hypderactivity Disorder
    Active substance: ATOMOXETINE
    Study summary document link (including results): atomoxetine B4Z-MC-LYBR - clinical study summary.pdf
    View full study record
    Document reference: 21974
    Study title: Children's Cancer Group 1962 Study : A randomized comparison of native E.coli asparaginase and polyethylene glycol asparaginase for treatment of children ith newly diagnosed standard-risk ALL
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21940
    Study title: A Double-Blind Crossover Study of Atomoxetine Hydrochloride and Methylphenidate Effects on Neural Acticity in Attention-Deficit/Hyperactiviity Disorder
    Active substance: ATOMOXETINE
    Study summary document link (including results): atomoxetine B4Z-MC-LYAU - clinical study summary.pdf
    View full study record
    Document reference: 21987
    Study title: Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine.
    Active substance: BENZATROPINE
    Study summary document link (including results):
    View full study record
    Document reference: 22252
    Study title: Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine.
    Active substance: BENZATROPINE
    Study summary document link (including results):
    View full study record
    Document reference: 41956
    Study title: Randomized, multicenter open study comparing the efficacy of potassium-phenoxymethylpenicillin V three times daily for 10 days versus benzathine penicillin V twice daily for 5 days in the treatment of acute group A ß-hemolytic streptococcal tonsillopharyngitis in childrenClinical efficacy and tolerance of bacampicillin and amoxycillin suspensions in children with acute otitis media; J Int Med Res. 1989 Jan-Feb;17(1):41-7.
    Active substance: BENZATHINE BENZYLPENICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 22276
    Study title: Randomized, multicenter pilot study comparing the efficacy of potassium-phenoxymethylpenicillin granules for oral suspension 100.000 IU /kg/day tid for 10 days versus benzathine-phenoxymethylpenicillin suspension 100.000 IU /kg/day bid for 7 days versus benzathine-phenoxymethylpenicillin suspension 100.000 IU /kg/day bid for 5 days in the treatment of acute group A ß-hemolytic streptococcal tonsillopharyngitis in childrenEffect on urogenital flora of antibiotic therapy for urinary tract infection; Scand J Infect Dis. 1990;22(1):43-7.
    Active substance: BENZATHINE BENZYLPENICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 22275
    Study title: Randomized, multicenter open study comparing the efficacy of potassium-phenoxymethylpenicillin V three times daily for 10 days versus benzathine penicillin V twice daily for 5 days in the treatment of acute group A ß-hemolytic streptococcal tonsillopharyn
    Active substance: BENZATHINE PHENOXYMETHYLPENICILLIN
    Study summary document link (including results): DV 2-99_Final Report_010531.pdf
    View full study record
    Document reference: 41960
    Study title: Randomized, multicenter pilot study comparing the efficacy of potassium-phenoxymethylpenicillin granules for oral suspension 100.000 IU /kg/day tid for 10 days versus benzathine-phenoxymethylpenicillin suspension 100.000 IU /kg/day bid for 7 days versus b
    Active substance: BENZATHINE PHENOXYMETHYLPENICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 41959
    Study title: Blake MJ, et all. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther. 2007 Apr;81(4):510-6. Epub 2007 Feb 14.Blake MJ, et all. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther. 2007 Apr;81(4):510-6. Epub 2007 Feb 14.
    Active substance: BENZILIC ALCOHOL + DEXTROMETHORPHAN
    Study summary document link (including results):
    View full study record
    Document reference: 22287
    Study title: Lehnert-W, Niederhoff-H, Junker-A, Saule-H, Frasch-W. A case of biotin-responsive 3-methylcrotonylglycin- and 3-hydroxyisovaleric aciduria. European journal of pediatrics, {Eur-J-Pediatr}, Oct 1979, vol. 132, no. 2, p. 107-14, ISSN: 0340-6199.Lehnert-W, Niederhoff-H, Junker-A, Saule-H, Frasch-W. A case of biotin-responsive 3-methylcrotonylglycin- and 3-hydroxyisovaleric aciduria. European journal of pediatrics, {Eur-J-Pediatr}, Oct 1979, vol. 132, no. 2, p. 107-14, ISSN: 0340-6199.
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22666
    Study title: Friebel-D, von-der-Hagen-M, Baumgartner-E-R, Fowler-B, Hahn-G, Feyh-P, Heubner-G, Baumgartner-M-R, Hoffmann-G-F. Department of Neuropaediatrics, Children's Hospital, Technical University of Dresden, Dresden, Germany. The first case of 3-methylcrotonyl-CoA carboxylase (MCC) deficiency responsive to biotin. Neuropediatrics, {Neuropediatrics}, Apr 2006, vol. 37, no. 2, p. 72-8, ISSN: 0174-304X.Friebel-D, von-der-Hagen-M, Baumgartner-E-R, Fowler-B, Hahn-G, Feyh-P, Heubner-G, Baumgartner-M-R, Hoffmann-G-F. Department of Neuropaediatrics, Children's Hospital, Technical University of Dresden, Dresden, Germany. The first case of 3-methylcrotonyl-CoA carboxylase (MCC) deficiency responsive to biotin. Neuropediatrics, {Neuropediatrics}, Apr 2006, vol. 37, no. 2, p. 72-8, ISSN: 0174-304X.
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22595
    Study title: Gompertz-D, Draffan-G-H, Watts-J-L, Hull-D. The Journal of pediatrics, {J-Pediatr}, Jul 1972, vol. 81, no. 1, p. 39-44, ISSN: 0022-3476. Biotin-responsive beta-methylcrotonylglycinuria. Lancet, {Lancet}, 3 Jul 1971, vol. 2, no. 7714, p. 22-4, ISSN: 0140-6736.Gompertz-D, Draffan-G-H, Watts-J-L, Hull-D. The Journal of pediatrics, {J-Pediatr}, Jul 1972, vol. 81, no. 1, p. 39-44, ISSN: 0022-3476. Biotin-responsive beta-methylcrotonylglycinuria. Lancet, {Lancet}, 3 Jul 1971, vol. 2, no. 7714, p. 22-4, ISSN: 0140-6736.
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22672
    Study title: Bartlett-K, Ng-H, Leonard-J-V. A combined defect of three mitochondrial carboxylases presenting as biotin-responsive 3-methylcrotonyl glycinuria and 3-hydroxyisovaleric aciduria. Clinica chimica acta; international journal of clinical chemistry, {Clin-Chim-Acta}, 15 Jan 1980, vol. 100, no. 2, p. 183-6, ISSN: 0009-8981.Bartlett-K, Ng-H, Leonard-J-V. A combined defect of three mitochondrial carboxylases presenting as biotin-responsive 3-methylcrotonyl glycinuria and 3-hydroxyisovaleric aciduria. Clinica chimica acta; international journal of clinical chemistry, {Clin-Chim-Acta}, 15 Jan 1980, vol. 100, no. 2, p. 183-6, ISSN: 0009-8981.
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22662
    Study title: Baumgartner-Matthias-R, Dantas-M-Fernanda, Suormala-Terttu, Almashanu-Shlomo, Giunta-Cecilia, Friebel-Dolores, Gebhardt-Boris, Fowler-Brian, Hoffmann-Georg-F, Baumgartner-E-Regula, Valle-David. Division of Metabolism and Molecular Pediatrics, University Children's Hospital, Zurich, Switzerland.. Isolated 3-methylcrotonyl-CoA carboxylase deficiency: evidence for an allele-specific dominant negative effect and responsiveness to biotin therapy. American journal of human genetics, {Am-J-Hum-Genet}, Nov 2004 (epub: 09 Sep 2004), vol. 75, no. 5, p. 790-800, ISSN: 0002-9297.Baumgartner-Matthias-R, Dantas-M-Fernanda, Suormala-Terttu, Almashanu-Shlomo, Giunta-Cecilia, Friebel-Dolores, Gebhardt-Boris, Fowler-Brian, Hoffmann-Georg-F, Baumgartner-E-Regula, Valle-David. Division of Metabolism and Mo...
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22598
    1  2  3  4  5  6  7  8  9  Next» Last»»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 16:36:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA